Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

Concord Repatriation & General Hospital ( Site 0203), Concord

St Vincent s Hospital (Melbourne) Limited ( Site 0202), Fitzroy

Monash Health ( Site 0201), Clayton

Princess Alexandra Hospital ( Site 0204), Woollongabba

Universitaetsklinikum Leipzig AOeR ( Site 0327), Leipzig

Fox Chase Cancer Center ( Site 0019), Philadelphia

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0352), Rozzano

A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 0351), Bologna

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0354), Meldola

U. klinikum Koeln AOER ( Site 0326), Cologne

Texas Oncology-Austin Midtown ( Site 8002), Austin

Banner MD Anderson Cancer Center ( Site 0020), Gilbert

Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007), Los Angeles

City of Hope ( Site 0001), Duarte

Pacific Cancer Care ( Site 0006), Monterey

University of California San Francisco ( Site 0023), San Francisco

Rambam Medical Center ( Site 0382), Haifa

Chaim Sheba Medical Center. ( Site 0380), Ramat Gan

Sourasky Medical Center ( Site 0381), Tel Aviv

Hadassah Ein Karem Jerusalem ( Site 0383), Jerusalem

Dana Farber Cancer Institute ( Site 0002), Boston

BC Cancer ( Site 0107), Vancouver

CancerCare Manitoba ( Site 0101), Winnipeg

Princess Margaret Cancer Centre ( Site 0100), Toronto

Jewish General Hospital ( Site 0105), Montreal